A New Step Forward in Lyme Disease Testing: Galaxy Diagnostics, Virginia Tech, and the LymeX Initiative

When it comes to Lyme disease, one of the biggest frustrations for both doctors and patients is the same: testing doesn’t always give clear answers.

The new collaboration between Galaxy Diagnostics and Virginia Tech is generating attention. Together, they’re working to develop a more reliable, next-generation diagnostic test for Lyme disease. This work ties directly into the broader LymeX Diagnostics Prize competition, a major national effort to accelerate breakthroughs in Lyme testing.

Why Better Lyme Tests Matter

Most current Lyme tests look for antibodies, the immune system’s response to infection with Borrelia burgdorferi. But antibodies can take weeks to develop. In early infection, test results often come back negative even when symptoms are present, leaving patients and clinicians in a gray zone.

For patients experiencing fatigue, joint pain, neurological symptoms, or flu-like illness after a tick bite, waiting weeks for clarity can feel overwhelming. For clinicians, it can mean difficult treatment decisions without firm diagnostic confirmation.

A Direct Detection Approach

Galaxy and Virginia Tech are taking a different tack: direct detection of bacterial components, rather than relying solely on immune response. The idea is to identify specific biomarkers, molecules shed by the bacteria itself, that could be detected earlier and more reliably.

Galaxy already offers a urine antigen test that uses innovative technology to capture and concentrate Borrelia proteins directly from patient samples, potentially identifying infections that traditional antibody tests miss.

The collaboration with Virginia Tech expands that work by integrating cutting-edge research on additional biomarkers like peptidoglycan fragments, which may circulate in the body during infection and could complement existing detection methods.

How LymeX Fits In

This effort is part of a larger national push. The LymeX Diagnostics Prize, led through a public-private partnership between the US Department of Health and Human Services and the Steven & Alexandra Cohen Foundation, is designed to spur innovation in Lyme disease diagnostics by providing funding, mentorship, and a structured pathway toward regulatory review.

The competition has already advanced through multiple phases, with teams refining promising approaches and planning clinical performance studies. Now underway, Phase 4 of the competition invites winning teams to execute clinical validation plans and submit their diagnostic technologies for potential clearance by the US Food and Drug Administration.

Galaxy’s work with Virginia Tech aligns with this mission, and the company was selected as one of only a few teams advancing in the LymeX challenge, underscoring the broader relevance of this collaborative strategy.

What This Means for Clinicians and Patients

For healthcare providers, better diagnostics mean:

• Earlier and more accurate detection of active infection
• Greater confidence in treatment decisions
• Fewer ambiguous or inconclusive results

For patients, this research represents real hope, not just in theory, but in the possibility of a test that could provide answers sooner and more reliably.

Looking Ahead

Clinical validation, regulatory review, and real-world adoption take time but this collaboration, backed by national innovation efforts like LymeX, represents meaningful advancement in Lyme diagnostics.

As Lyme disease continues to affect communities across the country, innovation in testing remains essential. For doctors seeking better tools and for patients seeking clearer answers, this partnership offers a hopeful step forward.

For More Information

Read the official press release from Galaxy Diagnostics.

Learn more about the LymeX Diagnostics Prize.